Chemoinformaics analysis of 3,4-dihydroxybenzaldehyde-diglucoside
| Molecular Weight | 138.122 | nRot | 1 |
| Heavy Atom Molecular Weight | 132.074 | nRig | 7 |
| Exact Molecular Weight | 138.032 | nRing | 1 |
| Solubility: LogS | -1.512 | nHRing | 0 |
| Solubility: LogP | 0.76 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 16 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 10 | No. of Aromatic Carbocycles | 1 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 6 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 7 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 6 |
| nHA | 3 | APOL | 18.0968 |
| nHD | 2 | BPOL | 6.88724 |
| QED | 0.448 |
| Synth | 2.05 |
| Natural Product Likeliness | 1.104 |
| NR-PPAR-gamma | 0.009 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0 |
| Pgp-sub | 0.004 |
| HIA | 0.014 |
| CACO-2 | -4.644 |
| MDCK | 0.0000102 |
| BBB | 0.084 |
| PPB | 0.684914 |
| VDSS | 0.615 |
| FU | 0.291074 |
| CYP1A2-inh | 0.549 |
| CYP1A2-sub | 0.091 |
| CYP2c19-inh | 0.047 |
| CYP2c19-sub | 0.059 |
| CYP2c9-inh | 0.04 |
| CYP2c9-sub | 0.677 |
| CYP2d6-inh | 0.027 |
| CYP2d6-sub | 0.293 |
| CYP3a4-inh | 0.148 |
| CYP3a4-sub | 0.116 |
| CL | 14.019 |
| T12 | 0.909 |
| hERG | 0.012 |
| Ames | 0.179 |
| ROA | 0.036 |
| SkinSen | 0.774 |
| Carcinogencity | 0.072 |
| EI | 0.985 |
| Respiratory | 0.966 |
| NR-Aromatase | 0.013 |
| Antiviral | No |
| Prediction | 0.873446 |